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ABSTRACT: The integration of a DNA copy of the viral RNA genome into host
chromatin is the deﬁning step of retroviral replication. This enzymatic process is catalyzed
by the virus-encoded integrase protein, which is conserved among retroviruses and LTR-
retrotransposons. Retroviral integration proceeds via two integrase activities: 3′-processing
of the viral DNA ends, followed by the strand transfer of the processed ends into host cell
chromosomal DNA. Herein we review the molecular mechanism of retroviral DNA
integration, with an emphasis on reaction chemistries and architectures of the nucleoprotein
complexes involved. We additionally discuss the latest advances on anti-integrase drug
development for the treatment of AIDS and the utility of integrating retroviral vectors in
gene therapy applications.
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1. INTRODUCTION
More than 100 years ago, the Danes V. Ellerman and O. Bang
and the American P. Rous passaged oncogenic variants of what
is known today as the avian sarcoma-leukosis virus (ASLV).1,2
The importance of retroviruses in biology and medicine has
greatly increased over the past 50 years with two major
milestones: ﬁrst, in 1981, the isolation of the human T-
lymphotropic virus 1 (HTLV-1)3 and, soon after, the discovery
of human immunodeﬁciency virus type 1 (HIV-1),4,5 which is
responsible for one of the most dramatic pandemics in recent
history. The ﬂurry of high-octane research, initially driven by
the suspected role of retroviruses in human cancer and later by
the acquired immunodeﬁciency syndrome (AIDS) pandemic,
yielded a plethora of discoveries and tools to bolster all
disciplines of biology.6 It would be hard to imagine cancer
biology without the concept of the oncogene or molecular
biology without reverse transcriptase (RT).
Retroviridae is a large viral family comprising seven genera: α-
through ε-retroviruses, lentivirus, and spumavirus (Table 1).
HTLV-1 and HIV-1 (along with their respective types) belong
to δ-retrovirus and lentivirus genera, respectively. Several other
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retroviral species gained prominence as research models, for
historical reasons or as animal pathogens. These include ASLV
(an α-retrovirus), mouse mammary tumor virus (MMTV, a β-
retrovirus), murine leukemia virus (MLV, a γ-retrovirus),
simian immunodeﬁciency viruses (SIVs, lentiviruses highly
related to HIV-1 and HIV-2), feline immunodeﬁciency virus
(FIV, a lentivirus), and the prototype foamy virus (PFV, a
spumavirus). Integration, which yields the establishment of the
obligatory proviral state,7 is the one feature that distinguishes
retroviruses from all other viral families. Herein, we present
state-of-the-art interpretations of the structure of retroviral
integrase (IN), the essential enzyme responsible for this
process, as well as the role of IN in virus replication. Due to
the conservation among IN proteins from diﬀerent retroviral
species, we will refer to them collectively as retroviral IN,
except when discussing aspects that may be relevant to a
particular retroviral genus or species.
2. IN AND THE RETROVIRAL LIFE CYCLE
Replication via formation of a stable DNA form makes
retroviruses particularly amenable to reverse genetics. Accord-
ingly, functions of retroviral gene products have been
extensively probed through mutagenesis. In early studies, IN
was identiﬁed as the protein product encoded within the 3′
portion of the retroviral pol gene that was essential for eﬃcient
retroviral replication and integration.8−11 Reverse transcription
of the diploid retroviral RNA genome results in the formation
of a linear double-stranded viral DNA (vDNA) molecule
carrying a copy of the long terminal repeat (LTR) sequence at
either end.12−15 The vDNA molecule exists in the form of a
preintegration complex (PIC)16,17 that is rather poorly
biophysically characterized due to the scarce level at which it
forms, ca. one copy per cell, during acute virus infection.
Nevertheless, PICs have been reported to contain a number of
cellular and viral proteins, most notably IN.18−26 Once the PIC
gains access to the nuclear compartment, the vDNA ends are
inserted into a cellular chromosome. This step, initiated by the
enzymatic action of IN and completed by the host cell DNA
repair machinery, is a point of no return: the cell becomes a
permanent carrier of the integrated viral genome, which is
referred to as the provirus.
In addition to this well-established role, IN may play a range
of less characterized functions in retroviral replication, as
suggested by its unusually complex genetics (reviewed in ref
27). For instance, disruption of the IN coding portion of the
HIV-1 pol gene can lead to production of viral particles with
aberrant morphology and severe defects in reverse tran-
scription.28−31 In fact, only a minority of HIV-1 IN mutants
display defects solely at the integration step of the viral life
cycle. Such mutants, which include amino acid substitutions
within the IN active site, were collectively categorized as class I
mutants.32 The hallmark of the associated phenotype is the
predictable accumulation of nonintegrated forms of vDNA,
including a circular form that contains two abutted copies of
the LTR (2-LTR circles). Conversely, class II HIV-1 IN
mutants disrupt viral replication at multiple steps while usually
retaining at least partial IN enzymatic activity in vitro.33−36 The
pleiotropic eﬀects observed with class II HIV-1 IN mutants
range from disrupted virion assembly to apparent nuclear
import defects.30,33,34,37−41 Most notably, class II IN mutants
typically show reduced levels of reverse transcription.27 The
abundance of HIV-1 IN mutations with pleiotropic phenotypes
is a strong indication that the protein may play critical roles in
the viral lifecycle outside of the integration step. Accordingly,
HIV-1 IN was shown to interact with the viral RT and inﬂuence
its activity in vitro.42−44 More recent work with allosteric IN
inhibitors (described at length below) has highlighted a direct
role for IN in HIV-1 particle maturation.45−47 Among the
esoteric functions of HIV-1 IN, its proposed involvement in
PIC nuclear import has been the subject of considerable and
yet to be resolved debate.34,40,41,48−54
3. ENZYMATIC STEPS IN RETROVIRAL DNA
INTEGRATION
3.1. Reactions Catalyzed by IN
Biochemical studies of retroviral DNA integration began with
partial puriﬁcation of enzymatically competent PICs from
acutely infected cells. Such preparations can catalyze vDNA
integration into exogenous DNA in vitro, and the reaction
products can be detected and quantiﬁed by Southern blotting
or PCR.16,55−58 During infection, a considerable fraction of
vDNA becomes circularized59−64 and, perhaps owing to the
circular nature of the bacteriophage λ DNA substrate for
integrative recombination,65 initial studies proposed that
retroviral integration proceeded through the 2-LTR circular
DNA form.66 However, subsequent experiments using native
MLV PICs demonstrated that it is the linear vDNA that serves
as the immediate precursor for integration.67,68 These landmark
studies also established two activities associated with the
PICs3′-processing and strand transfer67−70and retroviral
IN was shown to be suﬃcient to catalyze each of these
reactions in vitro.71−77
Table 1. Classiﬁcation of Retroviruses
subfamily genus species examples
duplication
size (bp)a
orthoretrovirinae α-retrovirus avian sarcoma-leukosis virus
(ASLV)
6
β-retrovirus mouse mammary tumor virus
(MMTV)
6
jaagsiekte sheep retrovirus
(JSRV)
human endogenous
retrovirus K (HERV-K)b
γ-retrovirus murine leukemia virus (MLV) 4 or 5
feline leukemia virus (FeLV)
reticuloendotheliosis virus
strain A (RevA)
human endogenous retrovirus
H (HERV-H)b
δ-retrovirus human T-lymphotropic
viruses 1 and 2 (HTLV-1,2)
6
bovine leukemia virus (BLV)
ε-retrovirus walleye dermal sarcoma virus
(WDSV)
?
lentivirus human immunodeﬁciency
viruses 1 and 2 (HIV-1,2)
5
maedi-visna virus (MVV)
equine infectious anemia virus
(EIAV)
feline immunodeﬁciency virus
(FIV)
spumaretrovirinae spumavirus prototype foamy virus (PFV) 4
bovine foamy virus (BFV)
feline foamy virus (FFV)
aSize of target DNA duplications ﬂanking integrated proviruses.
bExtinct as exogenous species.
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Retroviral IN bears no similarities to its namesake from λ
phage and is instead closely related to the DD(E/D) family of
DNA transposases.78 Crucially, the DNA cutting and strand
transfer reactions catalyzed by IN and transposases proceed
through phosphodiester transesteriﬁcation, without formation
of covalent protein−DNA intermediates.79−81 However, unlike
transposases, retroviral IN requires a prelinearized DNA
moleculethe product of reverse transcriptionand cannot
act on an integrated molecule that is ﬂanked by continuous host
DNA sequences. Therefore, while the active site of a
prokaryotic cut-and-paste transposase must carry out four
consecutive reactions,82,83 IN needs to accomplish only two, 3′-
processing and strand transfer, equivalent to the ﬁrst and the
ﬁnal steps in DNA transposition, respectively. These reactions
are carried by a multimer of IN assembled on vDNA ends,
referred to as the intasome (also known as the stable synaptic
complex), at the business end of the PIC (Figure 1a).17,84,85
During 3′-processing IN hydrolyses a phosphodiester bond at
either vDNA end, removing a di- or trinucleotide, liberating 3′-
hydroxyl groups attached to invariant 5′-CA-3′ dinucleotides.
The intasome can then bind host chromosomal DNA, forming
the target capture complex (TCC). Within the TCC, the
enzyme utilizes vDNA 3′-hydroxyls as nucleophiles to cut host
DNA in a staggered fashion, simultaneously joining both 3′
vDNA ends to apposing strands of host DNA. The postcatalytic
complex, referred to as the strand transfer complex (STC), is
subject to disassembly, which is likely accomplished by host cell
machinery.
The fact that 3′-processing of the vDNA can occur in the cell
cytoplasm21 presents a potential problem for retroviruses. The
high local concentration of vDNA in the conﬁnes of the PIC
makes it a potential target for strand transfer, and products of
viral self-integrationcalled autointegrationare readily de-
tectable in infected cells.86−88 It is obviously in the best interest
of retroviruses to avoid autointegration, and various mecha-
nisms have been identiﬁed. The barrier-to-autointegration
factor (BAF), a small DNA-binding protein that possesses the
unusual property to bridge and condense separate DNA
molecules together,89,90 was identiﬁed via its ability to suppress
the autointegration activity of MLV PICs in vitro.91 However, it
has yet to be determined whether BAF provides this function
during MLV infection, and the lentiviruses seem to utilize other
protective measures. The SET complex, which harbors a variety
of DNA metabolizing enzymes, can suppress autointegration
during HIV-1 infection,92 while the viral capsid (CA) protein
has been shown to play a role in regulating SIV auto-
integration.88 Additional work should help to clarify whether
there might be a universal mechanism or if, indeed, diﬀerent
viral species have evolved unique ways to protect themselves
from suicidal integration as they move through the cell toward
their preferred chromosomal DNA targets.
Recombinant IN proteins are generally proﬁcient in
supporting robust 3′-processing and strand transfer activities
on short double-stranded oligonucleotide substrates that
represent the U5 or U3 vDNA ends at the tips of the upstream
and downstream LTRs, respectively.71−74,76,77,93 However,
depending on the viral source and the method of enzyme
preparation, unpaired insertions of vDNA ends into target
DNA often account for the bulk of the strand transfer products
formed. HIV-1 IN is particularly prone to such aberrant strand
transfer events (referred to as half-site integration). Carefully
optimized HIV-1 IN in vitro assays developed over the past 15
years greatly improved the eﬃciency of paired integration of
vDNA ends (i.e., full-site or concerted integration).94−101
Conversely, some recombinant IN proteins, in particular PFV
IN, are far more proﬁcient at full-site strand transfer.102−104
Figure 1. Retroviral DNA integration pathway: reactions catalyzed by IN (a, blue arrows) and host cell enzymes (b, red arrows). The intasome
contains a multimer of IN (gray oval) assembled on vDNA ends. Following 3′-processing and nuclear entry, the cleaved intasome complex engages
cellular chromosomal DNA, forming the TCC. Insertion of the 3′ vDNA ends into host DNA results in formation of the STC with hemi-integrated
vDNA. Formation of the stable provirus further requires disassembly of the STC and repair of the strand discontinuities ﬂanking vDNA by the
sequential actions of a DNA polymerase, 5′-ﬂap endonuclease, and DNA ligase. Red dots represent magnesium ions in the intasome active sites.
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The underlying reasons for these diﬀerences between divergent
IN proteins are not fully understood. The propensity of HIV-1
IN to self-associate into higher-order multimers in solution105
could be a factor limiting its concerted integration activity in
vitro. A third type of reaction that IN can catalyze in vitro is
disintegration, representing a reversal of strand transfer.106
Although this reaction is unlikely to be relevant in vivo,
disintegration assays were instrumental to help map the
diﬀerent IN protein domains and the enzyme active
site.107−115 Having evolved to catalyze a single reaction cycle,
retroviral IN and transposases do not eﬀectively dissociate from
their reaction products, requiring active assistance from their
host cells to disassemble the STC.116,117 Because they do not
turn over, these enzymes are used in stoichiometric and often
superstoichiometric ratios to their DNA substrates.
3.2. Postintegration DNA Repair
Having executed concerted strand transfer to join both 3′
vDNA ends to host DNA, IN leaves a pair of single-stranded
gaps and short 5′ overhangs ﬂanking the vDNA, which are
repaired by cellular enzymes (Figure 1b; reviewed in ref 118).
Notwithstanding their importance, the ﬁnal steps of integration
are among the least studied aspects of retroviral replication.
Because disorderly repair of these discontinuities may lead to
disruption of proviral and chromosomal DNA integrity, the
handover of the retroviral hemi-integrant to the host DNA
repair machinery is likely an exquisitely choreographed process.
Disassembly of the thermodynamically stable STC complex
must be the ﬁrst step toward repair of the vDNA−chromosome
junctions. Active degradation of IN/transposase, which is well-
established in the bacteriophage Mu transposition system,116,117
may allow host cellular proteins to gain access to the sites of
repair. Consistent with this model, HIV-1 IN is subject to
ubiquitination and proteasome-dependent degradation when it
is ectopically expressed in human cells.119−121 RAD18, an E3
ubiquitin ligase involved in DNA gap repair, was shown to
interact with HIV-1 IN.122 However, a follow up study
observed that knockdown of RAD18 in target cells did not
reduce HIV-1 infectivity.123 Subsequently, von Hippel−Lindau
binding protein 1, a cellular subunit of the prefoldin chaperone,
was implicated in proteasome-mediated HIV-1 IN degradation
and, moreover, was shown to be required for eﬃcient viral
replication.124
Following STC disassembly, three separate DNA repair
enzymatic activities are required to complete the integration
process by joining 5′ vDNA ends to chromosomal DNA: a
DNA polymerase, a 5′ ﬂap endonuclease, and a ligase (Figure
1b). Early studies used biochemical approaches to test
candidate DNA cellular enzymes in repair of retroviral
integration products in vitro.125−128 Synthetic model DNA
containing a gap and 5′ overhang served as a template for
testing candidate proteins. In these experiments a cocktail of
host DNA repair proteins was challenged to polymerize across
the gap, to cleave the two-nucleotide ﬂap, and to ligate the
resulting product. Base excision repair (BER) pathway enzymes
DNA polymerase β, ﬂap endonuclease 1 (FEN1), and ligase I
were shown suﬃcient to repair the substrate.125 DNA
polymerase δ also supported repair in the presence of FEN1
and ligase I and was stimulated by its cofactor PCNA.
Alternatively, viral RT and IN have been proposed to mediate
postintegration repair.106 In this model, RT polymerizes across
the gap sequence, while 5′ ﬂap removal and ligation of both
strands are catalyzed by IN disintegration activity. However,
RT- and IN-dependent gap repair would require a complicated
juggling of the vDNA ends between the two viral enzymes and,
more problematically, would involve assembly of an unusual
complex with 5′ vDNA and freshly extended 3′ chromosomal
DNA ends in the IN active site. Even though RT is capable of
polymerizing through the gap in vitro, the reaction displayed
poor ﬁdelity.125 Moreover, addition of IN to the reaction did
not aﬀord completion of the repair process.125,127 Although
HIV-1 IN interacts with FEN-1129 and can stimulate its activity
in vitro,126 convincing evidence for a role of IN in repair of the
hemi-integrant during retroviral infection is lacking. Cell-based
studies have by contrast highlighted a role for the BER pathway
of oxidative DNA damage in lentiviral DNA integration.130,131
Other studies have described that the alteration of the
nonhomologous end-joining (NHEJ) pathway aﬀects retroviral
infection and survival of the infected cells.22,132−134 While some
have shown a role for active IN and, by extension, the vDNA
hemi-integrant, in NHEJ activation,132,134 a separate study
concluded that the linear vDNA substrate was cytotoxic to
cells.22
As a result of integration across the major groove in target
DNA and the subsequent gap repair, the proviral DNA is
ﬂanked by a short duplication of the target DNA sequence. The
duplication size is virus-speciﬁc and ranges from 4 bp for MLV
and PFV to 6 bp for HTLV-1, ASLV, and MMTV, while HIV-1
and other characterized lentiviruses generate 5-bp duplications
(Table 1).63,135−146
4. STRUCTURE OF RETROVIRAL IN
4.1. Domain Organization
IN proteins contain three conserved structural domains
common to all retroviral genera: the N-terminal domain
(NTD), the catalytic core domain (CCD), and the C-terminal
domain (CTD) (Figure 2a). Initially identiﬁed by limited
proteolysis of HIV-1 IN,108 the domains were characterized in
isolation using X-ray crystallography and/or nuclear magnetic
resonance (NMR) spectroscopy (Figure 2a).147−153 The NTD
folds into a compact three-helical bundle stabilized by
coordination of a Zn2+ ion by side chains of His and Cys
residues comprising the invariant HHCC motif.147,150 Often
misidentiﬁed as a “zinc ﬁnger domain”, the NTD is most
closely related to helix−turn−helix DNA binding domains.154
In spumaviral and ε- and γ-retroviral INs, the NTD is expanded
by a ∼40 amino acid residue NTD extension domain
(NED).85,155 The CTD is the least conserved of the three
canonical IN domains and features a Src homology 3 (SH3)-
like β-barrel fold.149,151 Although most structurally related to
the Tudor family of chromatin binding domains, the IN CTD
lacks the conserved hydrophobic cage used by Tudor domains
to bind methylated Lys and Arg residues. During integration,
the NTD and the CTD make important interactions with DNA
substrates and play critical structural roles within the intasome
assemblies.85,156,157 The ﬂexible linkers connecting these
domains to the CCD lack sequence conservation and vary in
length between retroviral genera.155,158
The CCD harbors the active site of the enzyme composed of
three invariant carboxylates comprising the signature D,D-35-E
motif.159 In isolation, the CCD can catalyze disintegration, but
neither of the biologically relevant activities of full-length
IN.112−114 Determined over 2 decades ago, the crystal structure
of the HIV-1 IN CCD revealed a protein fold shared by a
superfamily of nucleotidyltransferases, which notably includes
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bacterial and viral RNase H enzymes, Holliday junction
resolvase RuvC, prokaryotic and eukaryotic DD(E/D) trans-
posases, and RAG1 recombinase.148,160 This initial study and
the majority of subsequent IN crystal structures captured the
CCD in a recurring dimeric form (Figure 2a). Given the wide
separation of IN active sites in the CCD dimer, it became
immediately clear that a higher-order IN multimer must be
responsible for concerted integration of vDNA ends. Similarly,
four copies of the mechanistically related Mu phage transposase
assemble into its core synaptic complex, with only two of the
four protomers contributing active sites for the catalysis of
DNA cleavage and strand transfer.161−163 Of note, the HIV-1
virion packages as many as ∼250 copies of IN,164,165 a large
excess over the two active sites that are required to catalyze
integration.
Over the last 20 years, considerable eﬀort has been expended
to establish the functional multimeric state of retroviral IN. The
bulk of these studies has focused on HIV-1 IN, which was
shown to form a variety of multimeric species.166−172
Unfortunately, it is not obvious how the tendency of IN to
aggregate in solution relates to its active forms in complex with
vDNA. Indeed, well-studied transposases tend to form
functional multimers only when bound to their cognate DNA
substrates,173−175 which is explained by the involvement of
DNA in the synaptic interfaces.175−177 Due to perplexing
diﬃculties in obtaining soluble intasome preparations, the
functional state of HIV-1 IN has been particularly hard to
address. The tetrameric form of HIV-1 IN has so far received
the strongest experimental support,169,170 although evidence for
octameric states was also reported.178,179 The breakthrough
came from recent studies of nonlentiviral INs, which
fortuitously allowed assembly of monodisperse preparations
of the intasome complexes in vitro. Surprisingly, structural
characterization of three such intasomes established that the
functional multimeric states of IN proteins are not conserved
among retroviral genera. Thus, whereas PFV IN is monomeric
in solution and forms a tetramer within the intasome,85,103,180
Figure 2. Domain organization of HIV-1 IN. (a) Schematic of the
protein sequence with the NTD, CCD, and CTD shown as boxes
(top). Structures of the individual domains determined in isolation
(from left to right PDB IDs 1WJC, 1ITG, and 1IHV). Protein chains
are shown as cartoons, with zinc-coordinating residues His12, His16,
Cys40, and Cys43 and active site residues Asp64 and Asp116 shown as
sticks with carbon atoms in red. (b) Structure of a two-domain HIV-1
IN construct (PDB ID 1K6Y). Details of the key NTD−CCD
interface are shown as a blown up image to the right. Selected amino
acid residues are indicated. Dashes represent hydrogen bonds; gray
spheres are Zn2+ ions. All structural images in this review were
prepared using PyMOL software (http://www.pymol.org).
Figure 3. Structure of the PFV intasome. (a) Cleaved intasome complex (PDB ID 3L2Q) shown in two orthogonal views. Inner IN chains are
colored green and cyan, and outer chains are yellow. Individual IN domains are indicated; invariant IN active site carboxylates are shown as red
sticks; vDNA is shown as cartoons with transferred (i.e., the strand that IN acts upon) and nontransferred strands at each end shown in magenta and
beige, respectively. (b) Schematic of the intasomal tetramer with IN domains shown as ovals and colored by chain; curved lines represent NTD−
CCD (cyan and green) and CCD−CTD (black) linkers. Red circles represent inner IN chain active sites. (c) View on the IN active site prior to 3′-
processing. Active site carboxylates and catalytic metal ions are respectively shown as sticks and gray spheres. The invariant vDNA CA nucleotides
and their complements are letter-coded; the scissile 3′ dinucleotide is indicated.
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MMTV and ASLV INs are dimeric proteins that assemble into
octamers on vDNA ends.155,181
Initial hints for the structural organization of the diﬀerent IN
protomers within functional intasomes came from results of
biochemical complementation studies.168,182−184 Mutant IN
proteins that by themselves were defective for catalysis in vitro
could recover signiﬁcant levels of activity when studied as a
mixture. In this way, IN NTD and CCD functions were shown
to originate from diﬀerent protomers within the multimeric
complex. The ﬁrst glimpse into the structural basis for IN
multimerization beyond the canonical CCD dimerization was
provided by the crystal structure of a two-domain construct
spanning the NTD and the CCD of HIV-1 IN.185 The structure
revealed how pairs of IN dimers can interlock via formation of
cross-dimer NTD−CCD interfaces (Figure 2b). Subsequently
validated by site directed mutagenesis, the critical NTD−CCD
interface, predicted from prior biochemical studies, became the
second recurrent feature in structures of diverse INs and later
intasomes.85,155,157,181,186 Further details on the partial
structures of the preintasome era in retroviral IN structural
biology can be found in recent reviews.158,187,188
4.2. Architecture of the PFV Intasome
The ﬁrst functional retroviral IN−DNA complex found to be
amenable to structural characterization was the intasome from
the spumavirus PFV.85 Identiﬁed though comparative analysis
of diverse orthologs, PFV IN was shown to be highly soluble
and exceptionally active on short mimics of vDNA ends.103,189
The relatively simple architecture of the PFV intasome will
provide a basis to describe the structures of the more complex
α- and β-retroviral intasomes, which were characterized very
recently.155,181 Although the U5 and U3 ends of retroviral
LTRs are not identical, functional intasomes can generally be
assembled with pairs of U5 sequences. Snapshots of such
symmetrized PFV intasomes, visualized in the states prior to
and after 3′-processing, as well as in complex with target host
DNA prior to and after strand transfer, are now avail-
able.156,157,190
The PFV intasome (Figure 3a) contains a tetramer of IN
with a dimer-of-dimers architecture, composed of two
structurally and functionally distinct IN subunits. The inner
subunits (colored green and cyan in the ﬁgures) of each IN
dimer are responsible for all interactions with vDNA, including
provision of the active sites for catalysis. The outer IN subunits
(shown in yellow) attach to the inner chains via the canonical
CCD dimerization interface. The inner IN chains interact via
forming intersubunit NTD−CCD contacts, and the two halves
of the intasome are held together by the insertion of a pair of
CTDs, which act as solid spacers between the CCD dimers
(Figure 3a,b). The extended NTD−CCD and CCD−CTD
linkers run parallel to each other, trussing the nucleoprotein
assembly. The PFV intasome structures reported to date lack
outer IN chain NEDs, NTDs, and CTDs, which were
disordered in crystals and under cryo-electron microscopy
(cryo-EM) conditions.85,191 Some clues about the average
positions of the outer chain NTD and CTD could be gleaned
from solution-state X-ray and neutron scattering.180 However,
these domains are dispensable for PFV intasome assembly and
strand transfer activity in vitro, and their functions await
clariﬁcation.192
The vDNA ends enter the IN dimer−dimer interface,
providing both 3′ termini to the active sites of the inner IN
subunits. The CCD, CTD, and NED of both inner IN chains
make intimate interactions with the vDNA backbone and bases,
consistent with vDNA sequence speciﬁcity of retroviral IN.85
Three bases of each 5′ vDNA end are unpaired, tunneling
through the CCD−CTD interface to protrude from the sides of
the intasome structure (Figure 3c). Conceivably, such a
protein−DNA complex can only form when the recognition
sites are available on free vDNA ends, which makes the
integration process fundamentally irreversible once post-
integration repair is completed.
4.3. Engagement of Target DNA by the PFV Intasome
The PFV intasome assembled with bunt-ended vDNA ends
readily undergoes 3′-processing in the presence of Mg2+ or
Mn2+ ions.156 Following dissociation of the cleaved 3′-
dinucleotide, the saddle-shaped groove between the two halves
of the intasome becomes available for host cell (target) DNA
binding (Figure 4). The interaction primarily involves the
target DNA backbone, which explains only weak preferences of
IN for integration target site sequence.156,157,193 Target DNA
binds to the PFV intasome in a sharply bent conformation, such
that the base pair step at the center of the integration site
unstacks with a 60° roll (Figure 4).157 The associated expansion
of the major groove to over 26 Å allows the widely spaced
intasome active sites to align with a pair of phosphodiesters
separated by 4 bp on apposing strands in target DNA. The
ability of DNA to form a sharp kink contributes to integration
site selection at the level of nucleotide sequence, leading to a
bias against rigid purine−pyrimidine base pair steps in the
central positions of PFV integration sites.157,194 The energy of
DNA deformation is oﬀset by the interactions with the synaptic
CTDs and the inner IN CCDs of the PFV intasome.
Predictably, mutations aﬀecting these contacts can lead to
Figure 4. Target DNA capture by the PFV intasome. (a) Crystal
structure of the PFV TCC (PDB ID 3OS1). (b) Conformation of
vDNA and target DNA in the TCC (left) and STC (right, PDB ID
3OS0), with protein chains hidden for clarity.
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increased bias for a bendable target DNA sequence.157
Conversely, prebent and distorted DNA performs better as a
target for retroviral integration.195,196
The PFV intasome displays robust preference for chromati-
nized targets compared to naked DNA in vitro.191,197 These
observations agree with early studies that, albeit using poorly
deﬁned IN−vDNA complexes, reported preferences of HIV-1
and MLV for nucleosomes.195,196,198−200 Moreover, nucleotide
sequence periodicities observed in the immediate vicinity of
retroviral integration sites are consistent with nucleosomes
serving as targets for retroviral integration in vivo.194,201,202
Given the nonuniform availability of the major groove and the
structure of the underlying histone octamer,203 it is not
surprising that integration sites cluster in sharply deﬁned
hotspots along nucleosomal DNA. Recently, the PFV TCC
containing the intasome and a nucleosome core particle was
characterized by cryo-EM at 8 Å resolution (Figure 5a).191 The
structure revealed that nucleosomal DNA engaged in the target
DNA binding groove of the intasome is lifted from the surface
of the histone octamer to assume the distorted conformation
compatible with strand transfer. Outside of the target DNA
binding groove, the intasome makes supporting contacts with
one H2A−H2B heterodimer and the second gyre of the
nucleosomal DNA (Figure 5b). These interactions presumably
compensate for the energy of stretching and deforming histone-
wrapped DNA and explain the strong preference of PFV to
target superhelix ±3.5 locations on nucleosomal DNA.
The strand transfer reactions occurring within the TCC that
result in the joining of the 3′ vDNA ends to the host DNA
mark the end of IN catalytic function. Like 3′-processing, strand
transfer does not lead to global conformational rearrangements
within the intasome structure.156 It remains a mystery if and
how IN signals completion of strand transfer for recruitment of
STC disassembly and DNA repair machineries. Given the
apparent preference of retroviruses to integrate into nucleo-
somes,191,194,197 chromatin remodellers appear to be good
candidates for the job of STC disassembly.
4.4. Mechanics of the IN Active Site
Although the ﬁrst CCD structures were determined in the
1990s, the functional organization of the IN active site was
revealed only in the context of the functional PFV IN−DNA
complexes. Dubbed “the active site loop” in the early
literature,204 the IN residues connecting β5 and α4 of the
CCD, often including the essential Glu of the D,D-35-E motif,
are disordered in most partial IN crystal structures. As expected,
the region folds into a deﬁned structure through interactions
with the vDNA end (Figure 3c). Given a high degree of amino
acid conservation within the IN active site, the lessons learned
from the high-resolution PFV structures should be generally
applicable. Accordingly, the PFV intasome was successfully
used as a model to study active site inhibitors of HIV-1
IN.85,205,206
The active sites of retroviral IN and the related DD(E/D)
transposases contain three carboxylates, which serve to
coordinate a pair of essential divalent metal cofactors (Figure
6). Although both Mg2+ and Mn2+ are capable of supporting IN
activities, due to its greater abundance, the former metal ion is
believed to be primarily utilized in vivo.207,208 The general
mechanism of two-Mg2+-ion catalysis at a phosphodiester bond,
initially proposed in the early 1990s,209,210 has been
corroborated by a growing body of experimental and theoretical
work, including recent studies of Bacillus halodurans RNase
H.208,211−213 The primary coordination spheres of the Mg2+
ions include essential active site carboxylates, the substrate
phosphodiester, and the attacking nucleophile (a water
molecule in the case of RNase H). The strong preference of
Mg2+ for octahedral coordination enforces precise relative
positioning of the reactants and aids in destabilizing the target
phosphodiester group. During catalysis, the ions act as Lewis
acids, with metal A assisting in deprotonation of the
nucleophile and metal B neutralizing the negative charge
developing on the phosphorane intermediate. The ability of
Mn2+ to replace Mg2+ ion as a cofactor is explained by its
similar size, pKa, and coordination geometry. Flavors of the
two-Mg2+-ion mechanism are employed by a wide range of
structurally and functionally diverse enzymes, which also
includes protein kinases,214−216 DNA and RNA poly-
merases,214,217,218 and even ribozymes.219
Due to the absolute dependence of the retroviral IN active
site on its metal cofactors, it was possible to grow crystals of
wild type (WT) PFV IN engaged with its DNA substrates.
When exposed to Mg2+ or Mn2+ salts, such apo forms of the
intasome and the TCC readily undergo 3′-processing and
strand transfer “in crystallo”. Soaking the crystals in the
presence of Mn2+ for very short periods of time (suﬃcient for
diﬀusion of the salt through the crystal lattice but not catalysis)
allowed freeze trapping the fully engaged conﬁgurations of the
PFV nucleoprotein complexes in their ground states prior to 3′-
processing and strand transfer.156
For consistency with the RNase H literature, the ion
cofactors coordinated to PFV IN residues Asp185 and
Glu221 are designated metal A and metal B, respectively
(Figure 6). The third carboxylate, Asp128, and a nonbridging
Figure 5. PFV intasome engaged with a mononucleosome. (a)
Pseudoatomic model assembled by rigid body docking of the PFV
intasome (PDB ID 3L2Q) and nucleosome (PDB ID 1KX5)
structures into the cryo-EM map of the complex (EMDB ID 2992)
and shown in two orientations. Individual histones are color coded as
indicated. (b) Blow up of the regions boxed in the left side of panel a
showing IN contacts with H2A and H2B histones (left) and with the
second gyre of the nucleosomal DNA (right).
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oxygen atom from the scissile phosphodiester are shared
between both ions. In the pre-3′-processing state, the
octahedral coordination sphere of metal A is nearly perfect
and includes a water molecule positioned for an in-line
nucleophilic attack at the phosphorus atom of the scissile
phosphodiester (Figure 6a). Due to simultaneous bidentate
interactions with Glu221 and the phosphodiester, the environ-
ment of metal B cannot assume octahedral coordination. This
departure from the preferred coordination geometry of metal B
is thought to provide a destabilizing potential on the scissile
phosphodiester.208,212 Following 3′-processing and dissociation
of the cleaved dinucleotide, metal B remains coordinated to the
Figure 6. Conﬁgurations of the IN active site leading to 3′-processing (a, PDB ID 4E7I) and strand transfer (b, PDB ID 4E7K). Direction of
nucleophilic attack by a water molecule (W, panel a) or 3′-hydroxyl of vDNA (panel b) is indicated with blue arrows marked SN2. Red spheres
represent water molecules; lower TCC X-ray data resolution did not allow reﬁnement of water molecules in panel b.
Figure 7. Architecture of the α and β-retroviral intasomes. (a) Crystal structure of the ASLV STC (PDB ID 5EJK) in two orientations. Target DNA
is hidden in the top panel. The core IN tetramer containing inner and outer IN subunits and a pair of synaptic CTDs from the ﬂanking IN chains is
indicated. (b) Schematic of the intasomal IN octamer with IN domains shown as ovals and colored by chain. For clarity, CTDs and NTDs belonging
to the outer IN subunits and NTDs from the ﬂanking subunits present in the structures are not indicated in panel a or shown in panel c. (c) Pseudo-
atomic model of MMTV intasome based on cryo-EM data (PDB ID 3JCA and EMDB ID 6441).
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3′ oxygen atom of the processed vDNA end. Consequently, it
befalls metal B to activate the nucleophilic 3′ hydroxyl of vDNA
during strand transfer (Figure 6b). Thus, retroviral IN uses the
inherent symmetry of the two-Mg2+-ion mechanism to carry
out the consecutive reactions of hydrolysis and transester-
iﬁcation. Because the latter step does not change the number of
high-energy bonds, strand transfer should in principle be
reversible, at least for as long as the STC persists. However,
such unproductive reversal of strand transfer is prevented by
relocation of the newly formed phosphodiester out of the active
site.157 This reconﬁguration is likely driven by conformational
strain due to target DNA deformation, which is a conserved
feature of retroviral intasomes and DD(E/D) transpo-
sases.157,173,177,220−222
4.5. ASLV and MMTV Intasome Structures
In the PFV intasome, a pair of CTDs from the inner IN
protomers are inserted in the dimer−dimer interface. The
synaptic CTDs provide rigidity to the assembly and contribute
to the host DNA binding platform. Crucially, this architecture
depends on an extended polypeptide linker to track the linear
distance of ∼50 Å that separates the carboxyl terminal
boundary of the inner chain CCD to the beginning of the
CTD (depicted as a black curve in Figure 3b). Intriguingly, the
length of the CCD−CTD linker is not conserved among
retroviral IN proteins, ranging from 50 to 60 amino acid
residues in γ- and ε-retroviruses and spumaviruses, to less than
10 residues in α- and β-retroviruses, whereas lentiviruses and δ-
retroviruses possess intermediate-size linkers.155,158 Modeling
suggested that the lentiviral IN CCD−CTD linker may stretch
suﬃciently to allow formation of the tetrameric intasomal
architecture similar to that in PFV.205,223 However, this
scenario is clearly not conceivable in the cases of α- and β-
retroviral IN proteins.
Recently, the STC from ASLV and the intasome from
MMTV were characterized by X-ray crystallography at 3.8 Å
and cryo-EM at ∼5 Å resolution, respectively.155,181 Un-
expectedly, the structures revealed that the α- and β-
retroviruses maintain a PFV-like core intasomal structure by
employing additional IN dimers (referred to as ﬂanking dimers)
to source the pair of synaptic CTDs (Figure 7a,b). Strikingly,
these intasomes contain homo-octamers of IN, each with four
structurally and functionally distinct types of subunits. The
intasomal core structure is further decorated by NTDs and
CTDs belonging to the eight IN subunits. Locations of six
CTDs, including the four provided by the ﬂanking dimers, are
conserved between the ASLV and MMTV intasome structures,
and these make direct contacts with vDNA. The CCDs of the
ﬂanking IN dimers are considerably less deﬁned in the cryo-EM
structure, and their positions diﬀer between the ASLV and
MMTV intasomes (Figure 7a,c). Intriguingly, their locations
are consistent with their potential roles in interactions with host
DNA. Indeed, contacts between the ﬂanking CCDs and the
backbone of the target DNA are observed in the ASLV STC
(Figure 7a, bottom panel).181 Results of biochemical
complementation experiments moreover indicate that the
ﬂanking IN dimers are necessary for MMTV IN strand transfer
activity.155
5. INTEGRATION SITE SELECTION
5.1. Retroviral Integration Is Not Random with Respect to
the Target Genome
Depending on the genomic location, the local chromatin
environment of the provirus may be conducive to active viral
expression or transcriptional silencing. Thus, the choice of
integration site inﬂuences the level of ongoing viral replication
and may contribute to the establishment of latent viral
reservoirs.224−228 In fact, the propensity of HIV-1 to establish
chronic and hitherto incurable infection is the direct
consequence of its ability to establish latent reservoirs.225,229,230
While the interaction of IN with vDNA ends is nucleotide-
sequence- and structure-speciﬁc, the enzyme displays very little
selectivity with regard to the host DNA. Alignments of
retroviral integration sites revealed weak, virus-speciﬁc
palindromic sequence consensi that do not extend farther
than several bp from the integration site.193,194,231−233 These
weak nucleotide sequence preferences are in part explained by
the sparse interactions between IN and target DNA bases.157,194
However, far more interesting patterns emerge when the
distributions of retroviral integration sites are scrutinized on the
genomic scale.
Early research conducted in the 1970s and 1980s indicated
that MLV integration may be associated with sites of DNase I
hypersensitivity in the host cell genome.234−236 The availability
of the draft human genome sequence237,238 and the relative
ease of recovering vDNA−chromosomal junctions using PCR
allowed Bushman and colleagues to address the distribution of
HIV-1 integration sites in their landmark 2002 study.239 The
ﬁeld was subsequently bolstered by the advent of deep
sequencing, which now permits recovery of hundreds of
thousands of unique integration sites in a single infection
experiment.201,240−242 It has emerged that retroviruses display
distinct and contrasting preferences for various host cell
genomic features (reviewed in ref 243). Thus, HIV-1 and
other lentiviruses display strong preferences for transcription
units with a sharp bias toward highly expressed and intron-rich
genes.201,239,240,244 MLV and other γ-retroviruses strongly favor
promoter regions and DNase I hypersensitive sites in
general.194,235,236,241,242,245,246 In sharp contrast, the spumavirus
PFV disfavors genes and loci of active transcription.191,247,248 It
appears that the least selective retroviruses are from the α- and
β-retrovirus genera, which show nearly random integration site
distributions with respect to well-mapped genomic fea-
tures.244,249,250
Strong evidence implicated IN as a major determinant for
integration site selection. Thus, implanting MLV IN into HIV-1
results in a chimeric virus with integration site preference which
is closer to that of MLV.246 However, the same study found a
subtler role for viral gag gene products, and more recent work
has shown that amino acid substitutions in viral CA protein
have considerable bearing on HIV-1 integration site distribu-
tions.246,251,252 A hallmark of lentiviruses is their ability to infect
nondividing cells, with their PICs capable of traversing the
nuclear envelope through the nuclear pore complex
(NPC),253,254 while many other retroviruses need the nuclear
envelope to break down during mitosis to access host
chromatin.255−259 It seems plausible that CA may modulate
HIV-1 PIC nuclear entry pathways, potentially via interactions
with cleavage and polyadenylation speciﬁcity factor 6 (CPSF6)
and/or nucleoporins (NUPs), which are the constitutive
components of the NPC. HIV-1 CA has been shown to
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interact directly with CPSF6,260,261 NUP358,262 and
NUP153,263 and depletion of each of these factors signiﬁcantly
reduced the frequency of HIV-1 integration into gene-rich
regions.251,262,264,265 The involvement of several NPC
components in integration site selection is consistent with the
observation that HIV-1 PICs preferentially target highly
expressed genes in the nuclear periphery that are proximal to
the nuclear pore.266,267 Conversely, HIV-1 integration is
excluded from internal nuclear regions as well as from
lamina-associated domains.267
5.2. The Nexus between Lentiviruses and LEDGF/p75
Whereas roles of retroviral structural proteins in PIC traﬃcking
are only starting to transpire, the IN-dependent mechanisms of
integration site selection are well-established. Lentiviruses and
γ-retroviruses ﬁnd their preferred genomic locations via
recognition of speciﬁc chromatin-associated cellular proteins,
which act as receptors or tethering factors for the PICs. Lens
epithelium-derived growth factor (LEDGF) is a ubiquitous
cellular chromatin-associated protein,268 initially described as
transcriptional coactivator p75.269,270 Although a proposed
extracellular function of the protein or speciﬁc roles in lens
epithelium development were not corroborated, its misnomer
has persisted in use. The protein was identiﬁed as a dominant
HIV-1 IN binding partner in aﬃnity-capture and yeast two-
hybrid screening experiments171,271 and was later shown to
interact with and stimulate the enzymatic activities of divergent
lentiviral INs.102,272,273 LEDGF/p75 is composed of 530 amino
acid residues and contains two small structured domains: an N-
terminal PWWP domain and C-terminal IN binding domain
(IBD) (Figure 8a).274,275 An alternative splice form, LEDGF/
p52,269 lacks the IBD (Figure 8a) and consequently neither
interacts with IN nor has an eﬀect on integration.276 The
extended ﬂexible regions of LEDGF/p75 harbor a classical
importin α/β-dependent nuclear localization signal (NLS)277
and a pair of AT-hook motifs implicated in DNA binding.278,279
The PWWP domain belongs to the Tudor family and was
shown to bind nucleosomes trimethylated on Lys36 of the
histone 3 tail (H3K36me3), an epigenetic mark associated with
transcription elongation and enriched within transcription
units.280−282 Knockout of the gene encoding LEDGF does
not aﬀect cell proliferation in tissue culture but results in
enhanced neonatal mortality and developmental abnormalities
in mice.283,284 While its precise cellular functions remain to be
elucidated, LEDGF/p75 reportedly interacts with a range of
functionally diverse proteins, including the basal RNA polymer-
ase cofactor PC2, mRNA splicing factors, multiple endocrine
neoplasia type 1 protein product (menin), methyl CpG binding
protein 2 (MeCP2), the end-resection protein CtIP, tran-
scription factor JPO2, and the activating subunit of Cdc7
kinase.240,269,285−291 LEDGF/p75 was shown to recruit some of
the binding partners to chromatin,276,285,290 suggesting that it
may function as an adaptor protein in various chromatin-bound
transactions.
Knockdown of LEDGF/p75 abolished the ability of
ectopically expressed HIV-1 IN to bind chromatin, which
provided the ﬁrst hint about its role in lentiviral replica-
tion.24,276 However, the functional signiﬁcance of the LEDGF/
p75-IN interaction in vivo was initially unclear because the ﬁrst
attempts at LEDGF/p75 knockdown obstensibly failed to aﬀect
HIV-1 infectious titer and yielded only modest reductions in
integration.24,292−294 Since infection of each new cell depends
Figure 8. Interaction of LEDGF/p75 and ALLINIs with HIV-1 IN. (a) Schematic of LEDGF/p75 and p52 organization with NLS, AT-hooks, and
structural domains (PWWP and IBD) shown as boxes. (b) Crystal structure of the HIV-1 IN CCD dimer in complex with LEDGF/p75 IBD (PDB
ID 2B4J). (c) Details of the protein−protein interactions (rotated ∼90° counterclockwise from the boxed region in panel b). (d) Chemical
structures of selected ALLINIs; chemical groups mimicking LEDGF/p75 Asp366 and Ile365 are shown in red and blue, respectively. (e) Crystal
structure of ALLINI BI-D in complex with HIV-1 IN CCD (PDB ID 4ID1), aligned with the panel c projection.
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on a single-molecule integration event, even very limited levels
of chromatin-associated LEDGF/p75 can be suﬃcient to
support eﬃcient viral replication.295 Clearer results came
from infections conducted under conditions of intensiﬁed
LEDGF/p75 knockdown and genetic knockout, which revealed
considerable decreases of HIV-1 infectivity with the speciﬁc
defect at the integration step.295−299
The analysis of distribution of residual HIV-1 integration
sites in LEDGF/p75-depleted cells demonstrated a dramatic
loss of transcription unit targeting concomitant with a
signiﬁcant increase of integration near transcription start
sites.296,299,300 The WT phenotype can be rescued upon
restoration of LEDGF/p75 expression, conﬁrming a role of the
host factor in the targeting mechanism. Furthermore, by
swapping the PWWP domain of LEDGF/p75 for alternative
chromatin binding domains, it was possible to redirect HIV-1
integration toward chromatin regions bound by the heterolo-
gous tether.301−303 Collectively, the results support a model
whereby LEDGF/p75 acts as a chromatin-bound tether that
anchors the PIC by engaging its IN component in a direct
protein−protein interaction. The results of a recent study that
analyzed integration distribution patterns in cells knocked out
for LEDGF/p75, CPSF6, or both factors clariﬁed that the CA
binding protein CPSF6 predominantly directs the HIV-1 PIC
to actively transcribed euchromatin, where LEDGF/p75
determines positions of integration along gene bodies.265
LEDGF/p75 is additionally involved in HIV-1 latency by
recruiting, post-integration, host factors IWS1 and SPT6 to the
LTR, leading to the silencing of the provirus.226 Rapid silencing
of the integrated viral genome is frequently observed during
HIV-1 infection in proliferating CD4+ T cells.304−306 By
interacting with LEDGF/p75, HIV-1 integration and transcrip-
tional silencing may thus be coordinated to the establishment
of long-lived viral reservoirs.226
The solution structure of the LEDGF/p75 IBD, determined
using NMR, revealed a compact domain comprising a pair of
HEAT repeatlike α-helical hairpins.307 On the virus side, the IN
CCD is essential and minimally suﬃcient for the interaction
with LEDGF/p75, whereas the NTD is required for high-
aﬃnity binding.276 X-ray crystallography was used to visualize
atomic details of the virus−host interaction (Figure
8b,c).98,186,308 The hairpin loops at the tip of the elongated
IBD structure contact the IN CCD dimer, with side chains of
LEDGF/p75 residues Ile365 and Asp366 buried in a small
pocket at the CCD dimerization interface, making hydrophobic
interactions and a bifurcated hydrogen bond with the IN
backbone, respectively. The protein−protein interaction is
enhanced by intermolecular contacts involving Lys401, Lys402,
and Arg405 on the basic side of the IBD and a conserved
cluster of carboxylates on lentiviral IN NTDs.98 Crucially,
LEDGF/p75 contacts both the CCD and the NTD, which
cooperate in higher-order IN multimerization and intasome
assembly. It is not surprising, therefore, that the host factor
enhances tetramerization and the strand transfer activity of
HIV-1 IN in vitro.98,186,309 The pocket on the surface of the
HIV-1 IN CCD involved in the interaction with the host factor
has been targeted by small-molecule inhibitors, which in their
binding mode to IN mimic the interactions made by LEDGF/
p75 Ile365 and Asp36646,310−315 (Figure 8d,e; see section 6.3).
Surprisingly, these small molecules potently enhance IN
multimerization,310,311,315−317 presumably without contacting
the NTD.314,318
5.3. γ-Retroviruses and BET Proteins
As LEDGF/p75 was shown to target lentiviral integration, it
seemed possible that other retroviruses might similarly rely on
genus-speciﬁc cellular factors to direct integration toward
preferred genomic loci. Hence, it did not come as a surprise
Figure 9. Interaction of BET proteins with MLV IN. (a) Schematic of domain compositions of BRD2, BRD3, and BRD4. (b) Solution structure of
BRD4 ET domain in complex with the EBM of MLV IN (PDB ID 2N3K) shown in two orientations. BRD4 and IN residues participating in the
hydrophobic core of the interface are shown as sticks and are indicated.
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when it was discovered that γ-retroviruses hijack cellular
transcription factors as targeting factors.129,319−321 Highly
related transcription factors BRD2, BRD3, and BRD4 belong
to the bromodomain and extra-terminal (BET) family. These
proteins play major roles in transcription regulation322,323 and
had already been implicated in host−pathogen interac-
tions.324−326 The characteristic features of BET members are
two tandem bromodomains and a highly conserved extra-
terminal (ET) domain within their N- and C-terminal regions,
respectively (Figure 9a).243 Bromodomains belong to the well-
studied group of chromatin readers with speciﬁcity for
acetylated histone tails,327 while the ET domains were
implicated in binding a range of cellular and viral proteins.323
In particular, BRD4 was shown to recruit P-TEFb to its target
promoters to facilitate transcription elongation of cellular
genes.328 Papilloma viruses tether their genomes to mitotic
chromosomes via a direct interaction between the viral E2
protein and the C-terminal motif of BRD4, which allows stable
segregation of vDNA copies between daughter cells.326,329 The
latent nuclear antigen of Kaposi’s sarcoma associated
herpesvirus, essential for the viral episome maintenance and
transcription, interacts with the ET domains of BET
proteins.330,331
Pull down experiments revealed a direct high-aﬃnity
interaction of γ-retroviral INs with the ET domains of BET
proteins; moreover, the latter potently simulated IN strand
transfer activity in vitro.194,319−321 Finally, the function of BET
proteins in the context MLV replication was demonstrated
using small-molecule inhibitors of the bromodomain−chroma-
tin interaction as well as siRNA-mediated knockdown. The
small molecules inhibited MLV but not HIV-1 integration in a
dose-dependent manner.319−321 Notably, MLV integration sites
correlate with binding sites of BET proteins as determined by
chromatin immunoprecipitation studies.319,321,332 Treatment of
cells with BET inhibitors or a siRNA cocktail speciﬁc to
BRD2−4 mRNAs signiﬁcantly reduced the preference of MLV
to integrate near transcription start sites.319,320 As a
complementary approach, LEDGF/p75-BRD4 hybrid proteins,
containing the LEDGF/p75 PWWP and BRD4 ET domain,
retargeted MLV integration toward active transcription units
and away from transcription start sites,321 conﬁrming the major
role of the BET proteins in γ-retroviral integration site
selection.
Despite highly similar functional consequences, the structural
bases for binding of lentiviral and γ-retroviral IN proteins to
their cognate host factors are strikingly diﬀerent. In contrast to
lentiviruses, which engage the LEDGF/p75 IBD using a
quaternary assembly of IN domains (minimally a CCD dimer),
γ-retroviruses bind BET proteins using extended C-termini
characteristic to the INs of this genus.321,333,334 The solution
structure of the complex between the BRD4 ET domain and a
conserved C-terminal ET binding motif (EBM) of MLV IN
showed that the interaction involves the formation of an
intermolecular three-stranded antiparallel β-sheet (Figure
9b).335 The folding of the interface only occurs upon binding
of the two partners, as both the C-terminal tail of MLV IN and
the BRD4 ET domain loop are unstructured on their own. The
protein−protein interface contains a set of hydrophobic
interactions involving buried side chains from both β6 and β7
of MLV IN and residues from helices α1 and α2 and the β1
strand of the ET domain (Figure 9b). The interaction further
depends on complementary electrostatics between the
negatively charged amino acids from ET domain strand β1
and the highly conserved positively charged residues of MLV
C-terminal β7. Mutation of the critical conserved amino acids
showed a strong reduction of binding aﬃnity as well as a shift
of the integration pattern away from transcription start
sites.320,334−336 Interestingly, BRD4 residues involved in the
interaction with MLV IN were shown also to be important for
binding its cognate cellular cofactors.335 Therefore, it seems
likely that γ-retroviral IN evolved its C-terminal tail to mimic a
cellular BET binding protein in order to optimize integration
into transcriptionally active regions.
5.4. Integration Site Selection by Other Retroviruses and
LTR Retrotransposons
The mechanisms of integration site selection employed by
lentiviruses and γ-retroviruses present a remarkable case of
convergent evolution, with both genera usurping cellular
readers of the histone code to locate optimal target sites.
Therefore, it is tempting to speculate that other retroviral
genera may use similar strategies. It was recently reported that
HTLV-1 and other δ-retroviral INs speciﬁcally interact with the
B′ protein phosphatase 2A (PP2A) regulatory subunits;
moreover, recombinant B′ proteins stimulated concerted
integration activity of the δ-retroviral INs in vitro.337 Although
not a classic chromatin binder, PP2A was implicated in
dephosphorylating chromatin-resident targets.338,339 However,
it remains to be determined whether PP2A is involved in
directing δ-retroviral integration.
LTR retrotransposons, such as well-studied Ty and Tf
elements from budding and ﬁssion yeasts, share most features
of their replication cycle with retroviruses, although they
complete it within the cell where they reside.340 The
fundamental diﬀerence between a transposon and a virus is
that the fate of the former wholly depends on the ﬁtness of the
host organism. Therefore, yeast LTR retrotransposons avoid
instigating harmful insertional mutagenesis on the cell by
precisely targeting new integration events to safe loci, and they
achieve it by utilizing IN-binding host proteins. Thus, Ty5
retrotransposition is directed into transcriptionally silent
regions of the Saccharomyces cerevisiae genome via the
interaction between IN and the heterochromatin maintenance
protein Sir4p.341 Of note, the C-terminal peptide of Ty5 IN
engages a patch on Sir4p, which is also recognized by the
cellular interacting partner Esc1.342,343 Another S. cerevisiae
retrotransposon, Ty1, engages the AC40 subunit of RNA
polymerase III in a direct protein−protein interaction with IN,
for speciﬁc integration upstream of RNA polymerase III
transcribed genes.344
6. HIV-1 IN AS A TARGET FOR DRUG DEVELOPMENT
6.1. HIV-1 IN Strand Transfer Inhibitors (INSTIs)
Its essential role in viral replication and the lack of functional
equivalents in human cells made IN an ideal target for anti-
HIV/AIDS drug development. Intense interest and early
screening eﬀorts notwithstanding, the ﬁrst class of small
molecules capable of inhibiting HIV-1 replication by blocking
IN was reported only in 2000.345 The key to identiﬁcation of
these molecules was the use of preassembled HIV-1 IN−vDNA
complexes in screening assays.346 Empirical optimization of the
original “diketo acid” pharmacophore led to the discovery of
MK0518, now widely known as raltegravir (RAL),347,348 the
ﬁrst integrase strand transfer inhibitor (INSTI) to be approved
for the treatment of AIDS in 2007. Two more antiretroviral
drugs with an identical mode of action, elvitegravir (EVG) and
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dolutegravir (DTG), have entered clinical use since then
(Figure 10a).349,350
Consistent with the method of their initial identiﬁcation,
INSTIs engage the active site of IN only when it is in complex
with the vDNA end, competing with target DNA for binding to
the intasome.85 INSTIs speciﬁcally inhibit the strand transfer
reaction, although they are capable of aﬀecting 3′-processing at
greatly elevated concentrations.345,351 These small molecules
possess unusually tight binding to the HIV-1 intasome, with
dissociative half-times measuring in hours (for EVG or RAL) or
even days (for DTG).352,353 This property is likely very
important for an inhibitor that blocks function of a long-lived
complex, such as the PIC, which is geared for a one-oﬀ reaction
event: to be eﬀective, an INSTI must remain associated with
the intasome until the cell destroys the PIC.
Despite their apparent chemical diversity, the INSTIs share
two common functionalities: a Mg2+ chelating core, usually a
triad of oxygen atoms attached to a rigid scaﬀold (colored red
in Figure 10a), and a ﬂexibly linked aromatic side chain,
typically a halobenzyl group (shown in blue). Due to the
conservation of the retroviral IN active site, these small
molecules display broad-spectrum activity against diverse
retroviruses.103,354,355 Accordingly, the structural basis for
INSTI action could be characterized in the context of the
PFV intasome.85,205,206,356 Soaking the PFV intasome crystals
with the diﬀerent INSTIs invariably results in binding of the
drug at the active site. In each studied case, the small molecules
engaged the catalytic pair of Mg2+ ions in the IN active site
(Figure 10b).85 Here, the triad of metal-chelating heteroatoms
of the small molecule closely imitates interactions made by the
oxygen atoms of the scissile phosphodiesters and the respective
nucleophiles during 3′-processing and strand transfer.156 The
aromatic side chain of the INSTI assumes the position normally
occupied by the base of the deoxyadenosine on the processed
3′ vDNA end, intercalating between the base of the penultimate
deoxycytidine and a short 310 helix (designated η in Figure 10b)
containing conserved PFV IN residues Pro214 and Gln215,
which are equivalent to HIV-1 IN Pro145 and Gln146,
respectively. INSTIs also make variable contacts with PFV IN
Tyr212 (corresponding to HIV-1 IN Tyr143). In particular, the
oxadiazole ring of RAL stacks with the phenolic side chain
(Figure 10b, middle panel) and additionally makes a hydrogen
bond to the backbone amide of the Tyr residue. Other
compounds, such as EVG and DTG, make much less extensive
van der Waals contacts with the Tyr side chain.
Crucially, by directly engaging the catalytic metals and
displacing the 3′ vDNA nucleotide, the INSTIs are
incompatible with target DNA binding and strand transfer.
Figure 10. Inhibitors of HIV-1 IN strand transfer activity. (a) Chemical structures of a diketo acid (L-731,988) and the clinical INSTIs RAL, EVG,
and DTG. Metal chelating atoms and halobenzyl moieties of the INSTIs are shown in red and blue, respectively. (b) Active site of the PFV intasome
prior to (top) and after binding RAL (middle) or DTG (bottom). The 310 helix that participates in the interactions with the INSTIs is indicated as η.
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The requirement to displace the 3′ adenosine from its natural
position accounts for the slow kinetics of INSTIs binding to the
intasome.357 A further energetic penalty associated with
disengagement of a phosphodiester group from the Mg2+ ions
in the intasomal active site explains the relative ineﬀectiveness
of INSTIs to inhibit IN 3′-processing activity.156
Adapted to operate on the bulky DNA substrate, the
intasome harbors a voluminous active site, which is not ideal for
the development of small-molecule inhibitors. X-ray structures
of the PFV intasome prior to 3′-processing and strand transfer
elucidated additional features of the DNA substrates that could
potentially be mimicked in future INSTI design.156 Further-
more, design of small molecules that more completely ﬁll the
substrate envelope within the intasome active site could lead to
improved inhibitory properties.358
6.2. Viral Resistance to INSTIs
The clinical use of INSTIs has seen the emergence of HIV-1
variants with high-level resistance to RAL and EVG (for
detailed reviews see refs 359, 360). Although not yet
documented in INSTI naiv̈e cohorts, resistance to DTG has
been described in patients that initially failed RAL-based
therapy.361−363 Due to their identical modes of action, INSTIs
show substantially overlapping proﬁles of HIV-1 resistance
mutations. The major genetic pathways leading to RAL
resistance and virologic failure in patients are associated with
substitutions of HIV-1 IN residues Tyr143 (typically to Cys or
Arg), Asn155 (to His), and Gln148 (to His or Arg).364
Although, on their own, the primary substitutions result in
modest levels of drug resistance, their eﬀects are greatly
ampliﬁed by secondary mutations. Most notably, combinations
of Q148R/H with G140S/A in HIV-1 IN result in a loss of viral
susceptibility to RAL and EVG, as well as substantial levels of
resistance to DTG.361,362
In the absence of HIV-1 intasome crystals, the PFV model
was instrumental to shed some light on the mechanism of viral
resistance to INSTIs.206 The observation that the oxadiazole
ring of RAL interacts extensively with the aromatic side chain of
Tyr212 readily explained why substitutions of HIV-1 IN residue
Tyr143 cause viral resistance to RAL.85 Because EVG and DTG
make only weak contacts with the Tyr residue, their activities
are largely unaﬀected by its substitutions.206 In contrast to
Tyr212, PFV IN residues corresponding to HIV-1 Gln148 and
Asn155 (Ser217 and Asn224, respectively) do not make direct
interactions with the INSTIs. Nevertheless, akin to the eﬀects
of the analogous mutations in HIV-1 IN, S217H and N224H
reduced susceptibility of PFV IN to RAL in vitro.206,356 Crystal
structures revealed that the amino acid substitutions result in
subtle but signiﬁcant deformations of the intasomal active site.
Expectedly, binding of the relatively rigid INSTIs requires the
mutant active site to adopt a WT-like conformation. The
energetic cost associated with the rehabilitation of the active
site was proposed to be the reason for the apparent reduction
in drug binding aﬃnity.206 A Ser or an Ala residue at HIV-1 IN
position 140 is predicted to make direct contacts with the side
chain of His148, helping to explain the coevolution of the
G140S and Q148H mutations.206 Ostensibly, a conformational
adaptation to a large substrate, such as target DNA or
chromatin, which make extensive interactions outside of the
active site, will be oﬀset to a lesser degree than small-molecule
binding. The diﬀerence may provide the mutant viruses a
suﬃcient selective advantage in the presence of the drug. This
model accordingly predicts that INSTIs that make more
extensive interactions with immutable features of the IN active
site will be less aﬀected by mutations. Indeed, INSTIs such as
DTG and MK2048, which display relatively long dissociative
half-times from the WT HIV-1 intasome, are considerably less
aﬀected by the “shape-shifting” Q148H/R and N155H
mutations.356,361,362 These small molecules, commonly referred
to as second-generation INSTIs, tend to make van der Waals
contacts to the main chain of the β4-α2 loop of the IN active
site.206,356,358,365 Bulkier compounds, which occupy the
substrate envelope of the intasomal active site more completely,
tend to be more active against the classic RAL-resistant
strains.358 Additionally, main chain IN amides involved in the
interaction with the scissile phosphodiesters of the viral and
target DNA substrates may provide useful immutable bonding
points for the next-generation of INSTIs.156
6.3. Emerging Allosteric Inhibitors of HIV-1 IN
Despite the great success of the combinatorial therapeutic
approach against HIV/AIDS, new infections emerge from drug-
resistant strains. In addition to developing new derivative
compounds against current targets, new drugs that inhibit
untapped steps of the HIV-1 replication cycle are of great
importance. In the case of IN, the design of drugs that target
positions diﬀerent from the active site has the advantage of
remaining theoretically potent against INSTI-resistant strains.
Among the noncatalytic site inhibitors described so far, the
most promising molecules target the LEDGF/p75 binding
pocket at the HIV-1 IN CCD dimerization interface; these new
molecules, which go by a variety of names (see refs 366, 367 for
detailed reviews), will be referred to here as allosteric IN
inhibitors (ALLINIs, Figure 8d).
Results of biochemical and cell-based infection assays
provided initial evidence that the CCD−CCD interface might
serve as a target for antiviral drug development. X-ray
crystallography was used to screen for small-molecule binders
of the HIV-1 IN CCD, and micromolar concentrations of one
compound, 3,4-dihydroxyphenyltriphenylarsonium bromide,
which engaged the CCD dimer interface at a region that was
later conﬁrmed as the LEDGF/p/75 binding site, inhibited IN
3′-processing and strand transfer activities in vitro.368 Over-
expression of LEDGF/p75 IBD-containing proteins that lacked
chromatin-binding activity moreover inhibited HIV-1 repli-
cation at the integration step.295,369 Further highlighting the
host factor-binding pocket for drug development, the
combination of IBD protein overexpression with LEDGF/p75
knockdown could eﬀectively cripple HIV-1 infection.370
The most advanced ALLINIs, derived from quinoline-based
acetic acid, were independently discovered using two diﬀerent
approaches. Debyser and colleagues312 used the HIV-1 IN
CCD-LEDGF/p75 IBD cocrystal structure to screen in silico
for LEDGF/p75 binding site inhibitors, whereas another group
discovered highly similar small molecules in a high-throughput
screen for antagonists of IN 3′-processing activity.313,371
Optimized ALLINI compounds are highly potent, inhibiting
HIV-1 replication with eﬀective concentration 50% (EC50)
values in the low (∼10−100) nanomolar range.310,313,315,317
This family of small molecules induces IN multimerization and
inhibits IN catalysis310,311,316,317 and IN-LEDGF/p75 bind-
ing310−312,316,317 in vitro. Cocrystal structures of the inhibitors
with the IN CCD dimer revealed that the molecules are bona
ﬁde allosteric inhibitors, as they engage the LEDGF/p75
binding site, which is distal from the enzyme active
site.46,310−314,317 A crucial component of the ALLINI
Chemical Reviews Review
DOI: 10.1021/acs.chemrev.6b00125
Chem. Rev. XXXX, XXX, XXX−XXX
N
pharmacophore is the carboxylic moiety (shown red in Figure
8d), which hydrogen bonds with the backbone amides of IN
residues Glu170 and His171, mimicking the LEDGF/p75
Asp366 bidentate interaction with IN (Figure 8e). Another
important feature is an aromatic side chain (blue in Figure 8d),
which mimics hydrophobic interactions made by Ile365 of
LEDGF/p75.
Initial experiments expectedly unveiled inhibition of
integration during HIV-1 infection, with drug resistance
mapping to the IN coding portion of the viral pol gene.310,312
However, follow up work revealed that the compounds are far
more potent when they are present during the late phase of the
HIV-1 lifecycle as compared to the acute phase of infection,
when reverse transcription and integration occur.45,46,317,372
Consistent with the in vitro data, ALLINIs induce HIV-1 IN
multimerization in the context of virus particles, which results
in a catastrophic defect during virion maturation.45,46,372 The
viral ribonucleoprotein (RNP) complex, composed mainly of
viral RNA and nucleocapsid protein, is normally housed within
a conical core composed of the CA protein. ALLINIs
apparently uncouple the internal placement of the RNP within
the core, yielding so-called “eccentric” virions with the RNP
situated outside of the core, usually in association with the viral
membrane.45−47,372 Virion protein, RNA, and cellular tRNA
content are unaﬀected by ALLINI treatment,45,46,372,373 and the
defective virions accordingly support normal levels of
endogenous RT activity in vitro.45,373
When present during the acute phase of HIV-1 infection,
ALLINIs speciﬁcally inhibit integration without aﬀecting the
preceding reverse transcription step.45,46,310,312,315,317 Although
drug-treated particles enter target cells normally,45,46 they are
reportedly defective for reverse transcription, integra-
tion,45,46,315,372 and nuclear import of the PIC.372 Careful
comparisons of dose−response curves for inhibition of particle
maturation, reverse transcription, and HIV-1 infection,
however, suggest that the ability of the compounds to inhibit
virion maturation accounts for their full antiviral activity.47 In
other words, drug-treated viruses are defective for reverse
transcription because the misplaced RNP is unable to support
DNA synthesis in the subsequently infected cell, as compared
to a direct inhibition of reverse transcription by ALLINIs.
Intriguingly, the range of replication defects ascribed to
ALLINI-treated virions is reminiscent of the pleiotropic nature
of class II IN mutations on HIV-1 replication (section 2 above).
Moreover, class II IN mutant virus particles harbor an eccentric
RNP that is indistinguishable from the one induced by ALLINI
treatment.30,45,46,223 By extension, we suspect that the inability
to encapsidate the RNP into the viral core underscores the
majority of replication defects ascribed to class II HIV-1 IN
mutant viruses. The ability to form eccentric RNPs has been
shown to depend on the presence of viral RNA, indicating that
IN may normally engage the viral genome, either directly or
indirectly, to orchestrate RNP encapsidation into the viral
core.47
ALLINI potency is signiﬁcantly increased when target cells
are depleted for LEDGF/p75, suggesting that the host factor
can compete with the compounds during the acute phase of
infection.46,298,315,374 By contrast, LEDGF/p75 depletion or
overexpression does not inﬂuence drug potency during particle
assembly.45,46,297,315 As LEDGF/p75 associates constitutively
with chromatin,171,268,276 it seems that the inability of LEDGF/
p75 to compete for compound binding to IN during HIV-1
particle morphogenesis, which occurs at the cell periphery or
after the virus exits the cell, accounts for the unique
pharmacology of this anti-IN drug class.
As might be expected from their known binding site at the
IN CCD dimer interface, ALLINIs retain potency against
INSTI-resistant HIV-1 strains.312,316,317,375 Unfortunately,
ALLINIs seem to possess a relatively low genetic barrier to
resistance, as several mutations mapping to the LEDGF/p75
binding cavity that greatly reduce drug potency have been
described following ex vivo virus passage.310,312,315,316,375
Nevertheless, because these molecules perform well in concert
with INSTIs,316,375 their clinical development is of great
interest.
7. RETROVIRAL INTEGRATION AS A THERAPEUTIC
TOOL
Due to the natural trait to stably integrate their genetic cargo
into a cell chromosome, retroviruses have long been studied as
tools for corrective gene therapy (see ref 376 for a current
overview). Replication-defective vectors derived from MLV
were used in pioneering studies to correct a variety of crippling
diseases, including X-linked severe combined immunodeﬁ-
ciency (SCID-X1),377 Wiskott−Aldrich syndrome,378 and
chronic granulomatous disease.379,380 However, a signiﬁcant
number of patients from these trials developed severe adverse
eﬀects due to clonal expansion of the treated cells, leading to
leukemia.378,381−383 Detailed characterization revealed that
many of these genotoxic events resulted from the integration
of the MLV vector in the vicinity of a growth-promoting proto-
oncogene, such as LMO2.378,382−384 Deregulation of proto-
oncogene expression has long been known as a driver for
retroviral genotoxicity,385 and the safety of retroviral vectors for
human gene therapy applications has accordingly become a
major priority in their development. An optimized vector would
in theory eﬃciently express its transgene cargo over a long
period of time without displaying adverse side eﬀects on cellular
gene expression or physiology.
The propensity for MLV to target integration to cellular
promoters and enhancers,241,242,245 which was virtually
unknown during the planning stages of the initial SCID-X1
trials, in hindsight likely made MLV an unfortunate choice for
treatment. However, the ﬁeld now has a much broader
appreciation of how diﬀerent types of retroviruses target
potentially unsafe genomic features such as genes and enhancer
regions.243 In this vein, vectors based on α-retroviruses,386 β-
retroviruses,387 or spumaviruses,388 each of which targets genes
and enhancers to lesser extents than lentiviruses and γ-
retroviruses, respectively, might prove safer than MLV-based
vectors. The identiﬁcation of the mechanisms of integration
targeting for the lentiviruses and γ-retroviruses has additionally
opened up new approaches to vector design. As one example,
MLV-derived vectors show greatly reduced propensity to
integrate nearby transcriptional start sites in the presence of
BET protein inhibitors,319 raising the possibility of using such
inhibitors with MLV vectors in the clinic. Several drawbacks
however seem likely to limit such approaches. In addition to
potential small-molecule toxicity, MLV retained a partial
tendency to target promoter-proximal regions in the presence
of BET inhibitors such as JQ-1.319 Furthermore, MLV vector
titer was reduced signiﬁcantly by JQ-1 treatment due to
inhibition of integration.319−321 An alternative strategy is to
delete the IN C-terminal tail region that mediates BET protein
binding.321,334 Such vectors greatly reduce promoter-proximal
integration with only a modest eﬀect on vector titer.334,389 It
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will be instructive to determine the carcinogenic potential of
such IN deletion constructs in animal models of MLV
pathogenesis.
A separate approach to MLV vector modiﬁcation looks
extremely promising from initial clinical trials. The viral
promoter and enhancer, which are situated within the U3
region of the LTR, can be deleted, resulting in so-called self-
inactivating (SIN) vectors without severely aﬀecting reverse
transcription or integration.390 An SCID-X1 trial with an MLV
SIN vector has failed to detect evidence for leukemia during an
initial 1−3 year observational period, indicating that deletion of
the viral enhancer might go a long way to improve MLV-based
vector safety.391
As fusion proteins between the LEDGF/p75 IBD301−303 or
BET protein ET domain321 and chromatin binding modules
can eﬀectively retarget integration, such protein hybrids could
in theory be used to steer lentivirus or γ-retrovirus integration
out of harm’s way. For example, a LEDGF/p75-based fusion
harboring the HP1α heterochromatin protein yielded an overall
integration pattern that was remarkably similar to random.301 A
key drawback of such approaches is the requirement to express
the retargeting factor in the cells that will receive the retroviral
vector. This approach accordingly seems to hold considerably
less promise than the attempts to reduce or eliminate
genotoxicity through direct vector modiﬁcation.
Notwithstanding highly signiﬁcant genetropic integration
targeting by the lentiviruses, there is little evidence to suggest
an operational link between HIV-1 integration and carcino-
genesis. A primary reason may be the highly cytopathic nature
of infection: infected CD4-positive T cells, the primary targets
of the virus, display an average half-life of only ∼1.5 days.392
However, cancer-related genes are targeted about 5-fold more
frequently by HIV-1 PICs than expected.240 Integrations in the
vicinity of growth-promoting genes moreover can help to drive
the clonal expansion of cells that constitute the latent viral
reservoir.227,228 Numerous HIV-1 gene products, including the
surface envelope glycoprotein Gp120393 and viral protein R
(Vpr),394 are acutely cytopathic, and such genes are deleted
from HIV-based vectors. As is the case with MLV vectors, it is
critical to monitor HIV-based gene therapy trials for sites of
vector DNA integration by deep sequencing to catch potential
longitudinal emergence of dominant cell clones in patients.
As is the case with MLV SIN vectors, results of preliminary
clinical trials with HIV-based vectors look promising, with little
to no evidence for the type of clonal dominance that was
observed in initial MLV-based trials.395−398 The ability to safely
integrate a corrective transgene in a long-lasting target cell can
in theory be expected to go a long wayperhaps for a patient’s
lifetimeto correct certain debilitating diseases. The ﬁeld
accordingly cautiously awaits long-term follow up of ongoing
retroviral-based gene therapy trials.
8. PERSPECTIVES
During the past 30 years the ﬁeld of retroviral integration
progressed from an epitome of experimental hardship and
enigma to arguably the best-understood DNA recombination
system. Combined eﬀorts of academic groups and leading
pharmaceutical companies resulted in the discovery of potent
HIV-1 IN inhibitors, characterization of the ﬁrst cellular
cofactors of retroviral INs, and elucidation of the mechanistic
and structural details of retroviral integration.
One clear vector for future research will be expansion of the
intasome structure repertoire. In particular, elucidation of HIV-
1 or lentiviral intasome structure will be of great importance to
help the rational design of next-generation INSTIs and
improved ALLINIs. Furthermore, characterization of the
HIV-1 intasome may help to identify new pockets that are
potentially druggable by allosteric inhibitors. The development
of resistance to the antiretroviral drug arsenal is a major health
issue, making it important to ﬁnd new therapeutic strategies.
Many steps modulating retroviral integration are still poorly
described and would necessitate further investigation. Among
these is the mechanism by which retroviruses protect
themselves against autointegration. One could imagine the
development of small molecules that could be used to trigger
suicidal autointegration before the PIC encounters host
chromatin.
Another open question is the mechanism of retroviral STC
disassembly. Since the available TCC and STC structures are
very similar, how IN signals the completion of strand transfer to
the cell to allow DNA repair remains unknown. Unravelling the
mechanism and the cellular proteins involved in this process
may well lead to the development of new drugs targeting these
steps. A more detailed characterization of the unexpected role
of IN in HIV-1 particle morphogenesis could also lead to new
ways of inhibiting viral replication.
Studies on retroviral IN host factors have clariﬁed the
molecular mechanisms underlying integration site selection.
The recent description of MLV IN targeting factors BRD2−4
together with the lentiviral IN cofactor LEDGF/p75 estab-
lished the concept of bimodal tethering as a major mechanism
for integration site selection. These discoveries opened new
windows toward tuning the speciﬁcity of retroviral integration.
Future studies will elucidate if the other retroviral families rely
on similar pathways to select suitable chromatin environments
and will hopefully give important insights into improving the
safety of retroviral gene therapy vectors. Given the parallel
development of gene-editing technologies such as CRISPR
(clustered regularly interspaced short palindromic repeats)-
Cas9 (reviewed in ref 399), there has been in recent years a
resurgence of interest in human gene therapy. Yet, notwith-
standing its lauded eﬃciency, gene editing using CRISPR-Cas9
involves generation of a double-strand DNA break at the target
locus, a highly genotoxic chromosomal lesion in its own right.
Therefore, it remains to be seen which methodology might
evolve into a safer therapy approach in the future.
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ABBREVIATIONS USED
AIDS acquired immunodeﬁciency syndrome
ALLINI allosteric integrase inhibitor
ASLV avian sarcoma-leukosis virus
BAF barrier-to-autointegration factor
BER base excision repair
BET bromodomain and extraterminal domain (protein
family)
CA capsid
CCD catalytic core domain
CPSF6 cleavage and polyadenylation speciﬁcity factor 6
CRISPR clustered regularly interspaced short palindromic
repeats
Cryo-EM cryo-electron microscopy
CTD carboxy-terminal domain
DTG dolutegravir
EBM ET binding motif
EC50 eﬀective concentration 50%
ET extra-terminal
EVG elvitegravir
FEN-1 ﬂap endonuclease 1
FIV feline immunodeﬁciency virus
HIV human immunodeﬁciency virus
HTLV human T-lymphotropic virus
IBD integrase binding domain
IN integrase
INSTI integrase strand transfer inhibitor
LEDGF lens epithelium-derived growth factor
LTR long terminal repeat
MeCP2 methyl CpG binding protein 2
MLV murine leukemia virus
MMTV mouse mammary tumor virus
NED NTD extension domain
NHEJ nonhomologous end joining
NLS nuclear localization signal
NMR nuclear magnetic resonance
NPC nuclear pore complex
NUP nucleoporin
NTD amino-terminal domain
PFV prototype foamy virus
PIC preintegration complex
PP2A protein phosphatase 2A
RAL raltegravir
RNP ribonucleoprotein
RT reverse transcriptase
SCID-X1 X-linked severe combined immunodeﬁciency
SH3 Src homology 3
SIN self-inactivating
SIV simian immunodeﬁciency virus
STC strand transfer complex
TCC target capture complex
vDNA viral DNA
Vpr viral protein R
WT wild type
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(51) Limoń, A.; Devroe, E.; Lu, R.; Ghory, H. Z.; Silver, P. A.;
Engelman, A. Nuclear Localization of Human Immunodeficiency Virus
Type 1 Preintegration Complexes (PICs): V165A and R166A Are
Pleiotropic Integrase Mutants Primarily Defective for Integration, Not
PIC Nuclear Import. J. Virol. 2002, 76 (21), 10598−10607.
(52) Christ, F.; Thys, W.; De Rijck, J.; Gijsbers, R.; Albanese, A.;
Arosio, D.; Emiliani, S.; Rain, J. C.; Benarous, R.; Cereseto, A.; et al.
Transportin-SR2 Imports HIV into the Nucleus. Curr. Biol. 2008, 18,
1192−1202.
(53) Krishnan, L.; Matreyek, K. A.; Oztop, I.; Lee, K.; Tipper, C. H.;
Li, X.; Dar, M. J.; KewalRamani, V. N.; Engelman, A. The
Requirement for Cellular Transportin 3 (TNPO3 or TRN-SR2)
During Infection Maps to Human Immunodeficiency Virus Type 1
Capsid and Not Integrase. J. Virol. 2010, 84 (1), 397−406.
(54) De Houwer, S.; Demeulemeester, J.; Thys, W.; Rocha, S.; Dirix,
L.; Gijsbers, R.; Christ, F.; Debyser, Z. The HIV-1 Integrase Mutant
R263A/K264A Is 2-Fold Defective for TRN-SR2 Binding and Viral
Nuclear Import. J. Biol. Chem. 2014, 289 (36), 25351−25361.
(55) Brown, P. O.; Bowerman, B.; Varmus, H. E.; Bishop, J. M.
Correct Integration of Retroviral DNA in Vitro. Cell 1987, 49 (3),
347−356.
(56) Farnet, C. M.; Haseltine, W. A. Integration of Human
Immunodeficiency Virus Type 1 DNA in Vitro. Proc. Natl. Acad. Sci.
U. S. A. 1990, 87 (11), 4164−4168.
(57) Ellison, V.; Abrams, H.; Roe, T.; Lifson, J.; Brown, P. Human
Immunodeficiency Virus Integration in a Cell-Free System. J. Virol.
1990, 64 (6), 2711−2715.
(58) Engelman, A.; Oztop, I.; Vandegraaff, N.; Raghavendra, N. K.
Quantitative Analysis of HIV-1 Preintegration Complexes. Methods
2009, 47, 283−290.
(59) Gianni, A. M.; Smotkin, D.; Weinberg, R. A. Murine Leukemia
Virus: Detection of Unintegrated Double-Stranded DNA Forms of the
Provirus. Proc. Natl. Acad. Sci. U. S. A. 1975, 72 (2), 447−451.
(60) Shank, P. R.; Hughes, S. H.; Kung, H. J.; Majors, J. E.; Quintrell,
N.; Guntaka, R. V.; Bishop, J. M.; Varmus, H. E. Mapping
Unintegrated Avian Sarcoma Virus DNA: Termini of Linear DNA
Bear 300 Nucleotides Present Once or Twice in Two Species of
Circular DNA. Cell 1978, 15 (4), 1383−1395.
(61) Shank, P. R.; Varmus, H. E. Virus-Specific DNA in the
Cytoplasm of Avian Sarcoma Virus-Infected Cells Is a Precursor to
Covalently Closed Circular Viral DNA in the Nucleus. J. Virol. 1978,
25 (1), 104.
(62) Yoshimura, F. K.; Weinberg, R. A. Restriction Endonuclease
Cleavage of Linear and Closed Circular Murine Leukemia Viral DNAs:
Discovery of a Smaller Circular Form. Cell 1979, 16 (2), 323−332.
(63) Shoemaker, C.; Goff, S.; Gilboa, E.; Paskind, M.; Mitra, S. W.;
Baltimore, D. Structure of a Cloned Circular Moloney Murine
Leukemia Virus DNA Molecule Containing an Inverted Segment:
Implications for Retrovirus Integration. Proc. Natl. Acad. Sci. U. S. A.
1980, 77 (7), 3932−3936.
(64) Pang, S.; Koyanagi, Y.; Miles, S.; Wiley, C.; Vinters, H. V.; Chen,
I. S. High Levels of Unintegrated HIV-1 DNA in Brain Tissue of AIDS
Dementia Patients. Nature 1990, 343 (6253), 85−89.
(65) Mizuuchi, K.; Nash, H. A. Restriction Assay for Integrative
Recombination of Bacteriophage Lambda DNA in Vitro: Requirement
for Closed Circular DNA Substrate. Proc. Natl. Acad. Sci. U. S. A. 1976,
73, 3524−3528.
(66) Panganiban, A. T.; Temin, H. M. Circles with Two Tandem
LTRS Are Precursors to Integrated Retrovirus DNA. Cell 1984, 36,
673−679.
(67) Fujiwara, T.; Mizuuchi, K. Retroviral DNA Integration:
Structure of an Integration Intermediate. Cell 1988, 54 (4), 497−504.
(68) Brown, P. O.; Bowerman, B.; Varmus, H. E.; Bishop, J. M.
Retroviral Integration: Structure of the Initial Covalent Product and Its
Precursor, and a Role for the Viral in Protein. Proc. Natl. Acad. Sci. U.
S. A. 1989, 86 (8), 2525−2529.
(69) Roth, M. J.; Schwartzberg, P. L.; Goff, S. P. Structure of the
Termini of DNA Intermediates in the Integration of Retroviral DNA:
Dependence on in Function and Terminal DNA Sequence. Cell 1989,
58 (1), 47−54.
(70) Fujiwara, T.; Craigie, R. Integration of Mini-Retroviral DNA: A
Cell-Free Reaction for Biochemical Analysis of Retroviral Integration.
Proc. Natl. Acad. Sci. U. S. A. 1989, 86 (9), 3065−3069.
(71) Katzman, M.; Katz, R. A.; Skalka, A. M.; Leis, J. The Avian
Retroviral Integration Protein Cleaves the Terminal Sequences of
Linear Viral DNA at the in Vivo Sites of Integration. J. Virol. 1989, 63
(12), 5319−5327.
(72) Vora, A. C.; Fitzgerald, M. L.; Grandgenett, D. P. Removal of 3′-
OH-Terminal Nucleotides from Blunt-Ended Long Terminal Repeat
Termini by the Avian Retrovirus Integration Protein. J. Virol. 1990, 64
(11), 5656−5659.
(73) Katz, R. A.; Merkel, G.; Kulkosky, J.; Leis, J.; Skalka, A. M. The
Avian Retroviral IN Protein Is Both Necessary and Sufficient for
Integrative Recombination in Vitro. Cell 1990, 63 (1), 87−95.
(74) Craigie, R.; Fujiwara, T.; Bushman, F. The IN Protein of
Moloney Murine Leukemia Virus Processes the Viral DNA Ends and
Accomplishes Their Integration in Vitro. Cell 1990, 62, 829−837.
(75) Bushman, F. D.; Fujiwara, T.; Craigie, R. Retroviral DNA
Integration Directed by HIV Integration Protein in Vitro. Science 1990,
249, 1555−1558.
(76) Bushman, F. D.; Craigie, R. Activities of Human Immunode-
ficiency Virus (HIV) Integration Protein in Vitro: Specific Cleavage
and Integration of HIV DNA. Proc. Natl. Acad. Sci. U. S. A. 1991, 88,
1339−1343.
(77) Sherman, P. A.; Fyfe, J. A. Human Immunodeficiency Virus
Integration Protein Expressed in Escherichia Coli Possesses Selective
DNA Cleaving Activity. Proc. Natl. Acad. Sci. U. S. A. 1990, 87, 5119−
5123.
(78) Dyda, F.; Chandler, M.; Hickman, A. B. The Emerging Diversity
of Transpososome Architectures. Q. Rev. Biophys. 2012, 45 (4), 493−
521.
(79) Mizuuchi, K.; Adzuma, K. Inversion of the Phosphate Chirality
at the Target Site of Mu DNA Strand Transfer: Evidence for a One-
Step Transesterification Mechanism. Cell 1991, 66 (1), 129−140.
(80) Engelman, A.; Mizuuchi, K.; Craigie, R. HIV-1 DNA
Integration: Mechanism of Viral DNA Cleavage and DNA Strand
Transfer. Cell 1991, 67 (6), 1211−1221.
(81) Kennedy, A. K.; Haniford, D. B.; Mizuuchi, K. Single Active Site
Catalysis of the Successive Phosphoryl Transfer Steps by DNA
Transposases: Insights from Phosphorothioate Stereoselectivity. Cell
2000, 101 (3), 295−305.
(82) Reznikoff, W. S. Tn5 as a Model for Understanding DNA
Transposition. Mol. Microbiol. 2003, 47 (5), 1199−1206.
(83) Haniford, D. B. Transpososome Dynamics and Regulation in
Tn10 Transposition. Crit. Rev. Biochem. Mol. Biol. 2006, 41 (6), 407−
424.
(84) Chen, H.; Wei, S.-Q.; Engelman, A. Multiple Integrase
Functions Are Required to Form the Native Structure of the
Chemical Reviews Review
DOI: 10.1021/acs.chemrev.6b00125
Chem. Rev. XXXX, XXX, XXX−XXX
S
Human Immunodeficiency Virus Type I Intasome. J. Biol. Chem. 1999,
274 (24), 17358−17364.
(85) Hare, S.; Gupta, S. S.; Valkov, E.; Engelman, A.; Cherepanov, P.
Retroviral Intasome Assembly and Inhibition of DNA Strand Transfer.
Nature 2010, 464 (7286), 232−236.
(86) Shoemaker, C.; Hoffman, J.; Goff, S. P.; Baltimore, D.
Intramolecular Integration within Moloney Murine Leukemia Virus
DNA. J. Virol. 1981, 40, 164−172.
(87) Li, Y.; Kappes, J. C.; Conway, J. A.; Price, R. W.; Shaw, G. M.;
Hahn, B. H. Molecular Characterization of Human Immunodeficiency
Virus Type 1 Cloned Directly from Uncultured Human Brain Tissue:
Identification of Replication-Competent and -Defective Viral Ge-
nomes. J. Virol. 1991, 65, 3973−3985.
(88) Tipper, C.; Sodroski, J. Enhanced Autointegration in Hyper-
stable Simian Immunodeficiency Virus Capsid Mutants Blocked after
Reverse Transcription. J. Virol. 2013, 87 (7), 3628−3639.
(89) Zheng, R.; Ghirlando, R.; Lee, M. S.; Mizuuchi, K.; Krause, M.;
Craigie, R. Barrier-to-Autointegration Factor (BAF) Bridges DNA in a
Discrete, Higher-Order Nucleoprotein Complex. Proc. Natl. Acad. Sci.
U. S. A. 2000, 97 (16), 8997−9002.
(90) Skoko, D.; Li, M.; Huang, Y.; Mizuuchi, M.; Cai, M.; Bradley, C.
M.; Pease, P. J.; Xiao, B.; Marko, J. F.; Craigie, R.; et al. Barrier-to-
Autointegration Factor (BAF) Condenses DNA by Looping. Proc.
Natl. Acad. Sci. U. S. A. 2009, 106 (39), 16610−16615.
(91) Lee, M. S.; Craigie, R. A Previously Unidentified Host Protein
Protects Retroviral DNA from Autointegration. Proc. Natl. Acad. Sci. U.
S. A. 1998, 95 (4), 1528−1533.
(92) Yan, N.; Cherepanov, P.; Daigle, J. E.; Engelman, A.; Lieberman,
J. The SET Complex Acts as a Barrier to Autointegration of HIV-1.
PLoS Pathog. 2009, 5, e1000327.
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